Avid Bioservices Inc (CDMO)

[terrygd]

“Independent market research predicts that modified interferons will continue to be a keycomponent of therapy for hepatitis C patients, with interferon sales expected to exceed $5 billion in 2014.

More than 4 million people in the United States, and more than 200 million people worldwide, are currently infected with hepatitis C. The standard treatment for hepatitis C is pegylated, or long-acting, alfa interferon administered in combination with the anti-viral drug ribavirin. The size of the hepatitis C market for interferon is currently $3 billion, and according to independent market research modified interferons will continue to be a key component of therapy for hepatitis C patients, with interferon sales expected to exceed $5 billion in 2014. The currently available pegylated alfa interferon products require administration once per week for up to 48 weeks and are associated with substantial side effects, particularly during the period following each administration.